Literature DB >> 19782387

Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital.

Beatriz E Joven1, Raquel Almodovar, Loreto Carmona, Patricia E Carreira.   

Abstract

OBJECTIVE: To analyze the causes of death, survival, and risk factors for mortality in a large series of Spanish systemic sclerosis (SSc) patients followed over the last 25 years in a tertiary care university hospital.
METHODS: Demographic, clinical, and outcome data from all SSc patients followed in the rheumatology department were included in a database created in 1989. ANOVA, Kruskal-Wallis, or chi(2) tests were used to identify differences among groups; Kaplan-Meier analysis was used to estimate survival, and Cox proportional hazards regression analysis was used to identify factors associated with mortality.
RESULTS: A total of 204 patients were included, of whom 182 (89%) were women. Mean age at diagnosis was 49 +/- 17 years, and mean follow-up was 8 years. Over 1635 patient-years, 36 of 44 deaths were attributable to SSc: 28 related to cardiorespiratory involvement, 4 to peripheral vascular disease, 3 to gastrointestinal, and 1 to renal involvement. The main SSc-unrelated causes of death were malignancy (3 cases) and infections (2 cases). Survival rates from disease onset were 85, 75, and 55% at 5, 10, and 20 years, respectively, with poorer survival in patients with renal disease and pulmonary hypertension (PH). Independent prognostic factors for mortality were older age at diagnosis, diffuse skin involvement, proteinuria, PH, and elevated erythrocyte sedimentation rate.
CONCLUSIONS: Ten-year survival is over 70% in Spanish SSc patients. The main causes of death are lung and cardiac involvement, and to a lesser extent, peripheral vascular disease and coexisting malignancy. Diffuse subset, proteinuria, PH, elevated erythrocyte sedimentation rate and older age at diagnosis are the main risk factors for mortality. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782387     DOI: 10.1016/j.semarthrit.2009.06.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  17 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

Review 2.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 3.  Systemic sclerosis and the heart: current diagnosis and management.

Authors:  Chintan S Desai; Daniel C Lee; Sanjiv J Shah
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

4.  Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.

Authors:  Anji Xiong; Qingting Liu; Jiaxun Zhong; Yuzi Cao; Qilang Xiang; Ziyi Hu; Shifeng Zhou; Zhuoyao Song; Huini Chen; Yan Zhang; Hongxu Cui; Shiquan Shuai
Journal:  Adv Rheumatol       Date:  2022-03-30

Review 5.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

6.  Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran.

Authors:  Hadi Poormoghim; Elham Andalib; Arash Jalali; Afshin Ghaderi; Ali Ghorbannia; Nazanin Mojtabavi
Journal:  Rheumatol Int       Date:  2016-04-09       Impact factor: 2.631

7.  Mortality in systemic sclerosis-a single centre study from the UK.

Authors:  Gemma Strickland; John Pauling; Charlotte Cavill; Gavin Shaddick; Neil McHugh
Journal:  Clin Rheumatol       Date:  2013-06-29       Impact factor: 2.980

8.  Overall and sex- and disease subtype-specific mortality in patients with systemic sclerosis : An updated meta-analysis.

Authors:  Y H Lee
Journal:  Z Rheumatol       Date:  2019-03       Impact factor: 1.372

9.  Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Authors:  Fabian A Mendoza; Maryah Mansoor; Sergio A Jimenez
Journal:  Expert Opin Orphan Drugs       Date:  2015-11-23       Impact factor: 0.694

10.  Serum amyloid A is a marker for pulmonary involvement in systemic sclerosis.

Authors:  Katja Lakota; Mary Carns; Sofia Podlusky; Katjusa Mrak-Poljsak; Monique Hinchcliff; Jungwha Lee; Matija Tomsic; Snezna Sodin-Semrl; John Varga
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.